Organosulfur compounds from alliaceae in the prevention of human pathologies.
A strong association between elevated plasma low-density-lipoprotein (LDL) and the development of cardiovascular diseases (CVD) has been established. Oxidation of LDL (Ox-LDL) promotes vascular dysfunction, enhances the production and release of inflammatory mediators such as reactive oxygen species and contribute to the initiation and progression of atherosclerosis. In addition, Ox-LDL enhances the production and release of tumor necrosis factor (TNF-alpha), interleukin (IL)-6, arachidonic acid metabolites and nitric oxide (NO) that are responsible for various human pathologies including cancer. Organosulfur compounds (OSC) from alliaceae modulate the glutathione (GSH) redox cycle and inhibits NFkappa-B activation in human T cells. Furthermore, OSC bioactivities include antioxidant, antibacterial, anticarcinogenic, antiatherogenic, immunostimulatory, and liver protection potential.
Tapiero
Haim
H
Université de Paris-Faculté de Pharmacie CNRS UMR 8612, Châtenay Malabry, France. haimtapiero@aol.com
Townsend
Danyelle M
DM
Tew
Kenneth D
KD
D000498:Allyl Compounds / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism; D012307:Risk Factors; D013440:Sulfides / Q000737:chemistry / Q000627:therapeutic use
D000498:Allyl Compounds; D016588:Anticarcinogenic Agents; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D013440:Sulfides; C038491:allyl sulfide